Oral sessions summaries

Acute and Chronic Complications

Results of the eValuation of ERTugliflozinEffIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV)

Richard E. Pratley, MD; Samuel Dagogo-Jack, MD, DSc; Christopher P. Cannon, MD; Darren K. McGuire, MD, MHSc; David Z. Cherney, MD, PhD; Mark E. Cooper, MBBS, PhD

ADA 2020 - Oral session

Acute and Chronic Complications

DAPA-HF Update—Have We Lost SGLT2 Inhibitors to Cardiologists?!

John J.V. McMurray, OBE, BSc (Hons), MB, ChB (Hons), MD, FRCP, FESC; Mikhail N. Kosiborod, MD; Silvio E. Inzucchi, MD; Jeffrey M. Testani, MD, MTR

ADA 2020 - Oral session

Acute and Chronic Complications

Analyses of First Plus Recurrent Cardiovascular and Hospitalization Events in the CAROLINA Trial

Nikolaus Marx, MD

ADA 2020 - Oral session

Acute and Chronic Complications

Association of Frequency of Hypoglycemic Episodes with Incident Cardiovascular Events in Adults with Type 2 Diabetes Mellitus: A National Database Study

Aman Rajpal, MD

ADA 2020 - Oral session

Clinical Diabetes/Therapeutics

Efficacy and Safety of Dulaglutide 3 mg and 4.5 mg vs. Dulaglutide 1.5 mg: 52-Week Results from AWARD-11

Juan P. Frias, MD

ADA 2020 - Oral session

Clinical Diabetes/Therapeutics

Acute Declines in eGFR During Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE

Megumi Oshima, MD

ADA 2020 - Oral session

Clinical Diabetes/Therapeutics

Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

Jing Wei Li, MD

ADA 2020 - Oral session

Clinical Diabetes/Therapeutics

Quality of Life in People with Type 2 Diabetes following Initiation of Second-Line Therapy: DISCOVER

Suzanne V. Arnold, MD, MHA

ADA 2020 - Oral session

Clinical Diabetes/Therapeutics

Advanced Hybrid Closed-Loop Pivotal Safety Study

Bruce Bode, MD

ADA 2020 - Oral session

Clinical Diabetes/Therapeutics

FLAIR—An NIDDK-Sponsored International, Multisite Randomized Crossover Trial of AHCL vs. 670G

Richard M. Bergenstal, MD

ADA 2020 - Oral session

Clinical Diabetes/Therapeutics

New Zealand AHCL Randomized Crossover Trial

Martin de Bock, FRACP, PhD

ADA 2020 - Oral session

Clinical Diabetes/Therapeutics

Horizon Automated Glucose Control System Pre-pivotal Trial Data

Bruce A. Buckingham, MD

ADA 2020 - Oral session

Epidemiology/Genetics

New Data on Clinical Outcomes from the Diabetes Prevention Program Outcomes Study (DPPOS)

David M. Nathan, MD; Mark Molitch, MD; Ronald B. Goldberg, MD; Brandy M. Heckman-Stoddard, PhD, MPH;Jose A. Luchsinger-Stuart, MD, MPH

ADA 2020 - Oral session

Epidemiology/Genetics

Update from the TEDDY Study

Marian Rewers, MD, PhD; Qian Li, PhD; Kendra Vehik, PhD, MPH; William Hagopian, MD, PhD

ADA 2020 - Oral session

Epidemiology/Genetics

Twenty Years of Pediatric Diabetes Surveillance- What Do We Know and Why It Matters - The SEARCH for Diabetes in Youth Study

Jean M. Lawrence, ScD, MPH, MSSA; Amy K. Mottl, MD, MPH, FASN; Katherine A. Sauder, PhD; Catherine Pihoker, MD

ADA 2020 - Oral session

Epidemiology/Genetics

Population Health Efforts in the Prevention and Treatment of Diabetes

Natalie D. Ritchie, PhD; Matthew J. O’Brien, MD, MS; Brian J. Wells, MD, PhD; Simon Griffin, FRCGP, FMedSci

ADA 2020 - Oral session

Immunology/Transplantation

All-Cause Mortality over 16 Years in Look AHEAD

Rena R. Wing, PhD

ADA 2020 - Oral session

Immunology/Transplantation

Comparison of Pancreas vs. Islet Transplantation Outcomes from a Large Single Center

Braulio A. Marfil-Garza, MD

ADA 2020 - Oral session

Integrated Physiology/Obesity

New Insights from the Restoring Insulin Secretion (RISE) Study—Differences between Adults and Youth with Prediabetes and Type 2 Diabetes

Sharon Edelstein, ScM; Thomas A. Buchanan, MD; Kristina Utzschneider, MD; Kristen J. Nadeau, MD, MS

ADA 2020 - Oral session

Integrated Physiology/Obesity

Glycaemia, Beta-Cell Function, and Incretin Hormones Post-OGTT One Year after Gastric Bypass and Sleeve Gastrectomy in Patients with Morbid Obesity and Type 2 Diabetes: An RCT (Oseberg Study)

Farhat Fatima, MD

ADA 2020 - Oral session

Therapeutics/New Technology

Differences in Time-in-Range, Glycemic Variability, and the Glucose Management Indicator in Pregnant Women with Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes

Sarit Polsky, MD

ADA 2020 - Oral session

ADA 2020 Virtual Highlights are available on the Medfyle app